Literature DB >> 23757050

Hypertriglyceridemia accompanied by increased serum complement component 3 and proteinuria in non-nephrotic chronic kidney disease.

Kentaro Kohagura1, Masako Kochi, Tsuyoshi Miyagi, Takanori Kinjyo, Yuichi Maehara, Kojiro Kinjyo, Kazufumi Nagahama, Atsushi Sakima, Kunitoshi Iseki, Yusuke Ohya.   

Abstract

BACKGROUND: Hypertriglyceridemia (hTG) is a risk factor for progression of chronic kidney disease (CKD); however, it remains unknown whether the adipocytokine complement component 3 (C3) is involved in the association between hTG and CKD.
METHODS: The study included 138 patients (54 % male) with non-nephrotic (serum albumin ≥3 g/dl) CKD who had undergone a renal biopsy and did not have hypocomplementemic disease. Renal arteriolopathy was assessed semi-quantitatively. We examined the cross-sectional associations between proteinuria and hTG with or without a higher serum C3 level (hC3), defined as equal or above the median value.
RESULTS: The mean (SD) age of the patients was 42 (±17) years and urine protein was 1.2 (±1.2) g/gCr. Patients with hTG had a significantly higher urine protein than those without hTG. Subgroup analysis showed that the hTG+/hC3+ group had higher grade arteriolopathy and urine protein levels. Multiple logistic regression analysis adjusted for age, sex, and diabetes mellitus showed that hC3+ alone was associated significantly with higher levels of urine protein [odds ratio (OR), 2.98; 95 % confidence interval (CI) 1.19-7.46, p = 0.02]; however, hTG alone showed no such association. hTG+/hC3+ was a significant factor when hTG-/hC3- was used as the reference (adjusted OR 5.32; 95 % CI 1.40-20.17, p = 0.01), with this OR being decreased by adjustment for arteriolopathy.
CONCLUSIONS: hTG accompanied by hC3 was associated with proteinuria in non-nephrotic CKD. Arteriolopathy may influence this association. A prospective study is needed to determine the predictive value of this association in CKD progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23757050     DOI: 10.1007/s10157-013-0825-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  44 in total

1.  Triacylglycerols and body fat mass are possible independent predictors of C3 in apparently healthy young Brazilian adults.

Authors:  Ana Carolina Pinheiro Volp; Kiriaque Barra Ferreira Barbosa; Josefina Bressan
Journal:  Nutrition       Date:  2011-12-28       Impact factor: 4.008

Review 2.  Metabolic syndrome and kidney disease: a systematic review and meta-analysis.

Authors:  George Thomas; Ashwini R Sehgal; Sangeeta R Kashyap; Titte R Srinivas; John P Kirwan; Sankar D Navaneethan
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 8.237

3.  Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats.

Authors:  O Michel; D Heudes; I Lamarre; C Masurier; M Lavau; J Bariety; J Chevalier
Journal:  Kidney Int       Date:  1997-12       Impact factor: 10.612

4.  Dyslipidaemia and the progression of renal disease in chronic renal failure patients.

Authors:  Z A Massy; T Nguyen Khoa; B Lacour; B Descamps-Latscha; N K Man; P Jungers
Journal:  Nephrol Dial Transplant       Date:  1999-10       Impact factor: 5.992

5.  Complement C3 is a risk factor for the development of diabetes: a population-based cohort study.

Authors:  Gunnar Engström; Bo Hedblad; Karl-Fredrik Eriksson; Lars Janzon; Folke Lindgärde
Journal:  Diabetes       Date:  2005-02       Impact factor: 9.461

6.  Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study.

Authors:  Nick Wlazlo; Marleen M J van Greevenbroek; Isabel Ferreira; Eugene J H M Jansen; Edith J M Feskens; Carla J H van der Kallen; Casper G Schalkwijk; Bert Bravenboer; Coen D A Stehouwer
Journal:  Metabolism       Date:  2012-07-02       Impact factor: 8.694

7.  Body mass index and the risk of development of end-stage renal disease in a screened cohort.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Kozen Kinjo; Taku Inoue; Chiho Iseki; Shuichi Takishita
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

8.  Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan.

Authors:  Kazufumi Nagahama; Kunitoshi Iseki; Taku Inoue; Takashi Touma; Yosiharu Ikemiya; Shuichi Takishita
Journal:  Hypertens Res       Date:  2004-04       Impact factor: 3.872

9.  Proteinuria and the risk of developing end-stage renal disease.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Chiho Iseki; Shuichi Takishita
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.